MNPR
NASDAQ · Biotechnology
Monopar Therapeutics Inc
$71.42
+4.20 (+6.25%)
Open$68.02
Previous Close$67.22
Day High$72.25
Day Low$67.31
52W High$124.82
52W Low$50.07
Volume—
Avg Volume158.8K
Market Cap478.68M
P/E Ratio—
EPS$-2.17
SectorBiotechnology
Analyst Ratings
Strong Buy
19 analysts
Price Target
-42.2% upside
Current
$71.42
$71.42
Target
$41.31
$41.31
$22.89
$41.31 avg
$45.20
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 251.96M | 240.93M | 249.50M |
| Net Income | -49,856,785 | -48,544,141 | -56,777,530 |
| Profit Margin | -19.8% | -20.2% | -22.8% |
| EBITDA | -96,691,861 | -80,803,710 | -82,101,366 |
| Free Cash Flow | -37,656,070 | -41,639,536 | -51,685,705 |
| Rev Growth | +2.3% | +24.0% | -9.1% |
| Debt/Equity | 0.25 | 0.23 | 0.27 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $291.31 | +1.07% | 49.3 | 509.50B |
| AMGN | Amgen Inc | $460.42 | +0.03% | 26.5 | 248.84B |
| GILD | Gilead Sciences Inc | $166.89 | -0.41% | — | 208.28B |
| VRTX | Vertex Pharmaceuticals Inc | $547.09 | +0.85% | 34.5 | 137.12B |
| REGN | Regeneron Pharmaceuticals | $904.35 | +0.16% | 19.4 | 93.39B |
| ALNY | Alnylam Pharmaceuticals Inc | $155.94 | -0.46% | 7.7 | 20.98B |